Published in Gynecol Oncol on September 09, 2005
Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ (2008) 3.45
p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev (2009) 1.82
Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J Cell Mol Med (2009) 1.48
How to evaluate emerging technologies in cervical cancer screening? Int J Cancer (2009) 1.37
Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol (2011) 1.25
HPV testing as a triage for borderline or mild dyskaryosis on cervical cytology: results from the Sentinel Sites study. Br J Cancer (2011) 1.10
Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med (2007) 1.09
Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer (2009) 1.08
Detection and genotyping of human papillomavirus in self-obtained cervicovaginal samples by using the FTA cartridge: new possibilities for cervical cancer screening. J Clin Microbiol (2009) 1.08
Cervical cancer prevention--cervical screening: science in evolution. Obstet Gynecol Clin North Am (2007) 1.07
Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J Clin Microbiol (2012) 1.05
Reduced acquisition and reactivation of human papillomavirus infections among older women treated with cryotherapy: results from a randomized trial in South Africa. BMC Med (2010) 0.93
Neither one-time negative screening tests nor negative colposcopy provides absolute reassurance against cervical cancer. Int J Cancer (2009) 0.90
Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis (2013) 0.90
Cervical intraepithelial neoplasia and higher long term risk of cancer. BMJ (2007) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. J Virol Methods (2013) 0.89
An intelligent clinical decision support system for patient-specific predictions to improve cervical intraepithelial neoplasia detection. Biomed Res Int (2014) 0.88
Triage of women with low-grade cervical lesions--HPV mRNA testing versus repeat cytology. PLoS One (2011) 0.88
HPV E6/E7 mRNA testing is more specific than cytology in post-colposcopy follow-up of women with negative cervical biopsy. PLoS One (2011) 0.87
Nucleic acid sequence-based amplification assay for human papillomavirus mRNA detection and typing: evidence for DNA amplification. J Clin Microbiol (2010) 0.87
Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer (2011) 0.85
Use of HC2 to triage women with borderline and mild dyskaryosis in the UK. Br J Cancer (2011) 0.82
Comparison of the accuracy of Hybrid Capture II and polymerase chain reaction in detecting clinically important cervical dysplasia: a systematic review and meta-analysis. Cancer Med (2013) 0.82
Influence of loop electrosurgical excision procedure on subsequent acquisition of new human papillomavirus infections. J Infect Dis (2009) 0.81
Comparing the Performance of Hybrid Capture II and Polymerase Chain Reaction (PCR) for the Identification of Cervical Dysplasia in the Screening and Diagnostic Settings. Clin Med Insights Oncol (2013) 0.80
Evaluation of the Oncogenic Human Papillomavirus DNA Test with Liquid-Based Cytology in Primary Cervical Cancer Screening and the Importance of the ASC/SIL Ratio: A Belgian Study. ISRN Obstet Gynecol (2014) 0.80
Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci (2012) 0.80
HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice. Ecancermedicalscience (2012) 0.79
Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma. Ecancermedicalscience (2015) 0.78
Identification of women for referral to colposcopy by neural networks: a preliminary study based on LBC and molecular biomarkers. J Biomed Biotechnol (2012) 0.78
When to test women for human papillomavirus. BMJ (2006) 0.76
Quantitative survey of multiple CpGs from 5 genes identifies CpG methylation panel discriminating between high- and low-grade cervical intraepithelial neoplasia. Clin Epigenetics (2015) 0.75
Diagnostic value of MCM2 immunocytochemical staining in cervical lesions and its relationship with HPV infection. Int J Clin Exp Pathol (2015) 0.75
Microarray detection of human papilloma virus genotypes among Turkish women with abnormal cytology at a colposcopy unit. J Turk Ger Gynecol Assoc (2013) 0.75
E6/E7 mRNA testing for human papilloma virus-induced high-grade cervical intraepithelial disease (CIN2/CIN3): a promising perspective. Ecancermedicalscience (2015) 0.75
HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions. J Cancer (2016) 0.75
Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med (2001) 6.33
Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA (2001) 5.99
Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet (2006) 5.65
WHO multicentre randomised trial of misoprostol in the management of the third stage of labour. Lancet (2001) 5.25
Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet (1997) 4.38
Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ (2008) 3.45
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med (1999) 2.79
European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology (2008) 2.67
Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines. J Virol (1987) 2.55
Strategies for global control of cervical cancer. Int J Cancer (1995) 2.52
An Epstein-Barr virus (EBV)-determined nuclear antigen (EBNA5) partly encoded by the transformation-associated Bam WYH region of EBV DNA: preferential expression in lymphoblastoid cell lines. Proc Natl Acad Sci U S A (1986) 2.42
Antibodies against a synthetic peptide identify the Epstein-Barr virus-determined nuclear antigen. Proc Natl Acad Sci U S A (1984) 2.40
Four virally determined nuclear antigens are expressed in Epstein-Barr virus-transformed cells. Proc Natl Acad Sci U S A (1986) 2.34
Penile cancer: epidemiology, pathogenesis and prevention. World J Urol (2008) 2.14
Association of serum immunoglobulin G antibodies against human papillomavirus type 16 capsids with anal epidermoid carcinoma. J Natl Cancer Inst (1995) 2.01
BamHI E region of the Epstein-Barr virus genome encodes three transformation-associated nuclear proteins. Proc Natl Acad Sci U S A (1988) 1.91
p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat Rev (2009) 1.82
European guidelines for clinical management of abnormal cervical cytology, part 2. Cytopathology (2009) 1.74
Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer (2000) 1.58
Prospective seroepidemiological study of role of human papillomavirus in non-cervical anogenital cancers. BMJ (1997) 1.55
Variations in policies for management of the third stage of labour and the immediate management of postpartum haemorrhage in Europe. BJOG (2007) 1.51
Antibodies against synthetic peptides react with the second Epstein-Barr virus-associated nuclear antigen. EMBO J (1985) 1.48
Comparative evaluation of multidetector CT and MR imaging in the differentiation of adnexal masses. Eur Radiol (2008) 1.47
No serological evidence for non-sexual spread of HPV16. Lancet (1994) 1.47
Histological recurrence and depth of loop treatment of the cervix in women of reproductive age: incomplete excision versus adverse pregnancy outcome. BJOG (2011) 1.47
Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. Obstet Gynecol (1997) 1.45
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology (2004) 1.40
The management of failed first trimester pregnancy. Ir Med J (1997) 1.39
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Uterine cervical involvement in a patient with Wegener's granulomatosis. Am J Med (2000) 1.38
Characterization of a second Epstein-Barr virus-determined nuclear antigen associated with the BamHI WYH region of EBV DNA. Int J Cancer (1985) 1.38
HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer (2007) 1.30
Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res (2001) 1.26
Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol (1999) 1.26
Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland. Br J Cancer (2007) 1.25
Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis. J Infect Dis (1990) 1.25
Human papillomavirus infection, risk for subsequent development of cervical neoplasia and associated population attributable fraction. J Clin Virol (2001) 1.23
A novel and rapid PCR-based method for genotyping human papillomaviruses in clinical samples. J Clin Microbiol (2000) 1.23
Choice of oxytocic preparation for routine use in the management of the third stage of labour: an overview of the evidence from controlled trials. Br J Obstet Gynaecol (1988) 1.21
Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer (2002) 1.20
Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol (2001) 1.20
Interventions targeted at women to encourage the uptake of cervical screening. Cochrane Database Syst Rev (2002) 1.20
Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev (2000) 1.19
Sexual behaviour and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol (1999) 1.16
A low voltage diathermy loop for taking cervical biopsies: a qualitative comparison with punch biopsy forceps. Br J Obstet Gynaecol (1986) 1.16
Identification of human papillomavirus seroconversions. J Gen Virol (1995) 1.14
Combined effect of smoking and human papillomavirus type 16 infection in cervical carcinogenesis. Epidemiology (1998) 1.13
Breast cancer during pregnancy: a mini-review. Eur J Surg Oncol (2008) 1.12
Human papillomavirus infection and esophageal cancer: a nationwide seroepidemiologic case-control study in Sweden. J Natl Cancer Inst (1999) 1.11
Lymphoblastoid cell lines and Burkitt-lymphoma-derived cell lines differ in the expression of a second Epstein-Barr virus encoded nuclear antigen. Int J Cancer (1986) 1.10
Carcinoma of cervix with recent normal Papanicolaou tests. Lancet (1980) 1.10
European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology (2007) 1.09
Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens. Am J Obstet Gynecol (1996) 1.09
Cervical cancer incidence in young women: a historical and geographic controlled UK regional population study. Br J Cancer (2012) 1.07
Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study. Cancer Causes Control (1993) 1.07
The thickness and volume of LLETZ specimens can predict the relative risk of pregnancy-related morbidity. BJOG (2012) 1.07
Correlates of the spread of human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2000) 1.06
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer (2000) 1.06
Apoptosis in human endometrium and endometriosis. Hum Reprod Update (2004) 1.05
A prospective, seroepidemiological study of the role of human papillomavirus in esophageal cancer in Norway. Cancer Res (1997) 1.05
Human papillomavirus type 16 capsid proteins produced from recombinant Semliki Forest virus assemble into virus-like particles. Virology (1995) 1.05
Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer (1998) 1.04
Down-regulation of the EBV-encoded membrane protein (LMP) in Burkitt lymphomas. Int J Cancer (1987) 1.03
Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors. J Clin Microbiol (1991) 1.03
A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer (1996) 1.03
Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis (1996) 1.03
Information leaflets, verbal information and women's knowledge of abnormal cervical smears and colposcopy. J Obstet Gynaecol (2003) 1.03
Tumor necrosis factor a-11 and DR15-DQ6 (B*0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden. Cancer Epidemiol Biomarkers Prev (2000) 1.02
Structural analysis of the human papillomavirus type 16-E2 transactivator with antipeptide antibodies reveals a high mobility region linking the transactivation and the DNA-binding domains. Nucleic Acids Res (1991) 1.01
Have we dismissed ablative treatment too soon in colposcopy practice? BJOG (2007) 1.01
The disease associations of the antibody response against the Epstein-Barr virus transactivator protein ZEBRA can be separated into different epitopes. J Gen Virol (1995) 1.00
Combined effect of low-penetrant SNPs on breast cancer risk. Br J Cancer (2011) 1.00
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol (2007) 0.99
Does improving communication and information for women increase attendance at colposcopy in an inner city clinic? A randomised controlled trial. Eur J Gynaecol Oncol (2004) 0.99
A population-based five-year follow-up study of cervical human papillomavirus infection. Am J Obstet Gynecol (2000) 0.98
Nuclear DNA-binding proteins determined by the Epstein-Barr virus-related simian lymphotropic herpesviruses H. gorilla, H. pan, H. pongo and H. papio. J Gen Virol (1987) 0.97
No excess risk of cervical carcinoma among women seropositive for both HPV16 and HPV6/11. Int J Cancer (1999) 0.97
Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol (1991) 0.96
The impact of a quadrivalent human papillomavirus (types 6, 11, 16, 18) virus-like particle vaccine in European women aged 16 to 24. J Eur Acad Dermatol Venereol (2009) 0.95
The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev (2006) 0.95